GlobeNewswire Inc.··DelveinsightRA Drug Pipeline Accelerates: 75+ Companies Race to Launch 80+ Therapies
DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.
BMYCELGrABBVLLYNVS+4clinical trialsdrug development